With regard to overall cancer risk, randomized controlled trials and observational studies assessing the effect of TNF inhibitor treatment, primarily in rheumatoid arthritis and inflammatory bowel disease patients, have yielded inconclusive results [35,36]. The gene discussed is TNF; the disease is cancer.